查看文章

Clinical trials have strict eligibility criteria, potentially limiting external validity. However, while often discussed this has seldom been explored, particularly across cancer types and at variable time frames posttrial completion. We examined comprehensive registry data (January 2014 to June 2019) for standard first‐line treatments for metastatic colorectal cancer (CRC), advanced pancreatic cancer (PC), metastatic HER2‐amplified breast cancer (BC) and castrate‐resistant prostate cancer (CaP). Registry patient characteristics and outcomes were compared to the practice‐changing trial. Registry patients were older than the matched trial cohort by a median of 2‐6 years (all P = <.01) for the CRC, BC and PC cohorts. The proportion of Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0‐1 patients was lower for CRC (94.1% vs 99.2%, P = .001) and BC (94.9% vs 99.3%, P = .001). Progression‐free …